LGR5 interacts with HSP90AB1 to mediate enzalutamide resistance by activating the WNT/β-catenin/AR axis in prostate cancer.
10.1097/CM9.0000000000003538
- Author:
Ze GAO
1
;
Zhi XIONG
1
;
Yiran TAO
2
;
Qiong WANG
3
;
Kaixuan GUO
1
;
Kewei XU
1
;
Hai HUANG
1
Author Information
1. Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120, China.
2. Department of Urology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 528406, China.
3. Department of Urology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong 510515, China.
- Publication Type:Journal Article
- Keywords:
Androgen receptor;
Enzalutamide;
Heat shock protein 90,000 alpha B1;
LGR5 protein, human;
Prostate cancer;
Treatment resistance;
WNT/β-catenin signaling pathway
- MeSH:
Male;
Humans;
Phenylthiohydantoin/pharmacology*;
Benzamides;
Receptors, G-Protein-Coupled/genetics*;
Nitriles;
Cell Line, Tumor;
HSP90 Heat-Shock Proteins/metabolism*;
Drug Resistance, Neoplasm/genetics*;
Prostatic Neoplasms/drug therapy*;
beta Catenin/metabolism*;
Receptors, Androgen/genetics*;
Animals;
Mice;
Wnt Signaling Pathway/physiology*
- From:
Chinese Medical Journal
2025;138(23):3184-3194
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Enzalutamide, a second-generation androgen receptor (AR) pathway inhibitor, is widely used in the treatment of castration-resistant prostate cancer. However, after a period of enzalutamide treatment, patients inevitably develop drug resistance. In this study, we characterized leucine-rich repeated G-protein-coupled receptor 5 (LGR5) and explored its potential therapeutic value in prostate cancer.
METHODS:A total of 142 pairs of tumor and adjacent formalin-fixed paraf-fin-embedded tissue samples from patients with prostate cancer were collected from the Pathology Department at Sun Yat-sen Memorial Hos-pital. LGR5 was screened by sequencing data of enzalutamide-resistant cell lines combined with sequencing data of lesions with different Gleason scores from the same patients. The biological function of LGR5 and its effect on enzalutamide resistance were investigated in vitro and in vivo . Glutathione-S-transferase (GST) pull-down, coimmunoprecipitation, Western blotting, and immunofluorescence assays were used to explore the specific binding mechanism of LGR5 and related pathway changes.
RESULTS:LGR5 was significantly upregulated in prostate cancer and negatively correlated with poor patient prognosis. Overexpression of LGR5 promoted the malignant progression of prostate cancer and reduced sensitivity to enzalutamide in vitro and in vivo . LGR5 promoted the phosphorylation of glycogen synthase kinase-3β (GSK-3β) by binding heat shock protein 90,000 alpha B1 (HSP90AB1) and mediated the activation of the Wingless/integrated (WNT)/β-catenin signaling pathway. The increased β-catenin in the cytoplasm entered the nucleus and bound to the nuclear AR, promoting the transcription level of AR, which led to the enhanced tolerance of prostate cancer to enzalutamide. Reducing HSP90AB1 binding to LGR5 significantly enhanced sensitivity to enzalutamide.
CONCLUSIONS:LGR5 directly binds to HSP90AB1 and mediates GSK-3β phosphorylation, promoting AR expression by regulating the WNT/β-catenin signaling pathway, thereby conferring resistance to enzalutamide treatment in prostate cancer.
